Mount Sinai Hospital

Running trials

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing

  NCT07387263· Unity Health Toronto· Source

• Recruiting

  Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

  NCT07245732· Phase 4· Sunnybrook Health Sciences Centre· Source

• Recruiting

  The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

  NCT06455384· Unity Health Toronto· Source

• Recruiting

  Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

  NCT07227961· University of Calgary· Source

• Recruiting

  Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic

  NCT06805773· Mount Sinai Hospital, Canada· Source

• Enrolling by invitation

  Clinical Utility of ClarityDX Prostate

  NCT06678828· Nanostics· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Evaluation of a Simple-Prep Controlled Embolic

  NCT06453642· Fluidx Medical Technology, Inc.· Source

• Recruiting

  Changes in Velocimetric Indices of Uterine and Umbilical Arteries Before and After Combined Spinal-epidural Analgesia in Laboring Women (PART II)

  NCT06655675· Samuel Lunenfeld Research Institute, Mount Sinai Hospital· Source

• Recruiting

  Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

  NCT06619860· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

  NCT06116136· Phase 1/2· Servier Bio-Innovation LLC· Source

• Active, not recruiting

  Cognitive Health Awareness Program in Surgical Patients

  NCT06540638· University Health Network, Toronto· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection

  NCT06004739· Mount Sinai Hospital, Canada· Source

• Recruiting

  Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty

  NCT06123715· Phase 3· University Health Network, Toronto· Source

• Recruiting

  Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients

  NCT06305273· Mount Sinai Hospital, Canada· Source

• Recruiting

  This is a Randomized Study of Early Involvement of Palliative Care Along Side Standard Treatment Versus Standard Treatment Alone in Newly Diagnosed Patients With Advanced or Metastatic Soft Tissue Sarcoma (SARQUALITY)

  NCT06805669· Mount Sinai Hospital, Canada· Source

• Recruiting

  Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study

  NCT06285396· Samuel Lunenfeld Research Institute, Mount Sinai Hospital· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Gilead Sciences· Source

• Recruiting

  A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

  NCT05762107· Phase 2· Zucara Therapeutics Inc.· Source

• Recruiting

  Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

  NCT05114096· Phase 4· McMaster University· Source

• Active, not recruiting

  Predicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose Monitoring

  NCT04972955· University of Manitoba· Source

• Recruiting

  Type 1 Diabetes Virtual Self-management Education and Support

  NCT05756829· Unity Health Toronto· Source

• Recruiting

  PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

  NCT05756244· University of Calgary· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Recruiting

  Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

  NCT04895839· Gabriela Ilie· Source

• Recruiting

  RA-PRO PRAGMATIC TRIAL

  NCT04692493· Phase 3· University of Alabama at Birmingham· Source

• Recruiting

  Abatacept for the Treatment of Giant Cell Arteritis

  NCT04474847· Phase 3· University of Pennsylvania· Source

• Recruiting

  Diet Intervention Treatment for Active Ulcerative Colitis

  NCT04121806· Mount Sinai Hospital, Canada· Source

• Recruiting

  Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  NCT04031677· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Active, not recruiting

  Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

  NCT03941132· Phase 2/3· University of British Columbia· Source

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Active, not recruiting

  Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

  NCT04068103· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  Association of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2

  NCT04187612· Samuel Lunenfeld Research Institute, Mount Sinai Hospital· Source

• Active, not recruiting

  Surveillance AFter Extremity Tumor surgerY

  NCT03944798· McMaster University· Source

• Active, not recruiting

  Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

  NCT04041310· Phase 1/2· Nouscom SRL· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

• Active, not recruiting

  Fit-for-Fertility Multicenter Randomized Controlled Trial

  NCT03908099· Université de Sherbrooke· Source

• Active, not recruiting

  Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

  NCT03765450· Alimentiv Inc.· Source

• Active, not recruiting

  Effects of Telemonitoring on the Outcome of Heart Failure Patients After an Incidence of Acute Decompensation

  NCT03358303· University Health Network, Toronto· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Showing 50 of 58.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sarcoma4 recruiting
• Colorectal cancer3 recruiting
• Prostate cancer3 recruiting
• Crohn's disease2 recruiting
• Gestational diabetes2 recruiting
• Giant cell arteritis2 recruiting
• High blood pressure2 recruiting
• Rheumatoid arthritis2 recruiting
• Type 1 diabetes2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Diabetic neuropathy1 recruiting
• Epilepsy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Acorai Machine Learning Generalization (MLG) Study

  NCT05835024· Acorai AB· Source

• Completed

  RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

  NCT05513560· Phase 2/3· University Health Network, Toronto· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  IBD Neoplasia Surveillance RCT

  NCT05809999· Ottawa Hospital Research Institute· Source

• Completed

  The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

  NCT05025852· Mount Sinai Hospital, Canada· Source

• Completed

  Optimum Length of Catheter in the Epidural Space for Labor Analgesia in Non-obese Women: a Randomised Controlled Trial of 4 cm Versus 5 cm

  NCT04946032· Samuel Lunenfeld Research Institute, Mount Sinai Hospital· Source

• Completed

  Family History App in Personalized Medicine

  NCT04726319· University of Toronto· Source

• Completed

  Low Molecular Weight hEparin vs. Aspirin Post-partum

  NCT05058924· Mount Sinai Hospital, Canada· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· University of Calgary· Source

• Completed

  Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

  NCT04440592· Phase 2· Tanabe Pharma America, Inc.· Source

• Terminated

  A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

  NCT04633447· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  The Effect of a Head Elevated Positioning Device on Position, Height and Depth of the Cricothyroid Membrane in Morbidly Obese Pregnant Women in the Third Trimester.

  NCT04569539· Samuel Lunenfeld Research Institute, Mount Sinai Hospital· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  Interactive Online Informational and Peer Support App for Patients with Low Anterior Resection Syndrome

  NCT04469426· Jewish General Hospital· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes

  NCT03215069· Phase 3· Mount Sinai Hospital, Canada· Source

• Completed

  Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

  NCT03261206· Phase 4· Alimentiv Inc.· Source

• Completed

  Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

  NCT04402645· Mount Sinai Hospital, Canada· Source

• Completed

  Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

  NCT03397108· The Hospital for Sick Children· Source

• Completed

  A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

  NCT03213457· Phase 3· AbbVie· Source

• Completed

  Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

  NCT03376438· Edgar Jaeggi· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

  NCT02108860· Phase 3· University of South Florida· Source

• Completed

  A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

  NCT02075840· Phase 3· Hoffmann-La Roche· Source

• Completed

  The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

  NCT01940094· Phase 3· University of Pennsylvania· Source

• Recruiting

  Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

  NCT00315380· University of Pennsylvania· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease52 works · 8 trials
• Sarcoma36 works · 6 trials
• Ulcerative colitis23 works · 5 trials
• ANCA-associated vasculitis7 works · 4 trials
• Neurofibromatosis type 13 works · 0 trials